We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

3 High-Yield Dividend Stocks For The Next Bear Market: GlaxoSmithKline plc, Pearson plc And G4S plc

Should you buy shares in GlaxoSmithKline plc (LON:GSK), Pearson plc (LON:PSON) & G4S plc (LON:GFS) for their dividends?

| More on:

You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.

When stock markets go awry, high yield stocks tend to outperform the broader market. The high-yielding dividend stocks that perform best in a downturn are so-called defensive ones. These are stocks in companies that provide goods and services always needed throughout the business cycle, enabling them to generate stable profits year after year.

Here are three high-yield stocks that could protect your portfolio in a bear market.

Should you buy Pearson Plc shares today?

Before you decide, please take a moment to review this report first. Despite ongoing uncertainties from US tariffs to global conflicts, Mark Rogers and his team believe many UK shares still trade at substantial discounts, offering savvy investors plenty of potential opportunities to learn about.

That’s why this could be an ideal time to secure this valuable research – Mark’s analysts have scoured the markets to reveal 5 of his favourite long-term ‘Buys’. Please, don’t make any big decisions before seeing them.

Controversial

GlaxoSmithKline (LSE: GSK) may be a controversial pick given its poor earnings trend. But as healthcare needs are continually rising, GSK remains a big growth opportunity. And despite recent weak results, it maintains a strong competitive position and has robust free cash flow generation.

Early signs of recovery are also beginning to show, with quarterly sales figures highlighting strong growth from its new pharmaceutical products, especially its new respiratory drug line-up including recently launched Breo, Anoro and Incruse. New products account for just £2bn in annual sales, but with continued sales growth and additional launches, sales could rise to £6bn by 2018.

Meanwhile, investors are being handsomely rewarded for their patience, with shares in the pharma giant currently yielding 5.5%. There’s one major short-term negative: with the dividend being frozen at 80p per share for 2016 and 2017, there’s no dividend growth for at least two years.

Transition

Pearson (LSE: PSON) is going through a rough patch, reporting a 2% drop in adjusted operating profits in 2015 and management giving a weak set of guidance figures for 2016. Adjusted operating profits are expected to come between £580m and £620m in 2016, which at the mid-point implies a decline of 13% on the previous year.

There are causes for optimism though. Pearson‘s competitive position is strong, and cyclical and policy factors are mainly to blame for recent weakness. This included a buoyant employment market in the US, which meant reduced college enrolment, and policy changes in the UK that lowered demand for its vocational course services.

The outlook in the longer term remains attractive. Pearson has significant exposure to growing markets in Brazil, China, India and South Africa, where it’s launching new products such as the New Student Experience. Its transition from print to digital would also likely be positive to its competitive position, given the advantage scale has on digital platforms.

With an annual dividend of 52p per share, Pearson yields 6%.

Market leader

Investor confidence in G4S (LSE: GFS) is near an all-time low, with the company seemingly embroiled in an endless list of controversies, ranging from overcharging of government contracts, human rights violations and abuse at a young offenders centre. But the company is still set to deliver strong underlying growth in revenues and earnings.

G4S remains global market leader in security services and against the backdrop of global economic uncertainty, demand for its services remains robust. In 2015, it secured new contract sales worth £2.4bn with retention rates near 90%. This shows the company has little trouble in winning new contracts even after recent scandals.

City analysts expect underlying EPS will grow 5.6% this year, to 15.2p per share. For 2017, earnings should climb another 9%, to 16.6p. This would put the shares on an attractive forward P/E of 12.2 and 11.2, respectively.

The stock’s 5.1% yield isn’t as big, but there’s potential for faster future dividend growth, given that earnings growth is set to accelerate.

Jack Tang has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Illustration of flames over a black background
Investing Articles

Hot, hotter, hottest. Is it too late to consider these 3 FTSE 100 shares?

James Beard looks at the three best- performing FTSE 100 stocks over the past year. But are they still worth…

Read more »

Young female analyst working at her desk in the office
Investing Articles

The only FTSE 100 stock I own right now

Muhammad Cheema reveals the only share he owns in the FTSE 100. However, that doesn’t mean he’s not a fan…

Read more »

Investing Articles

Are Greggs shares about to go gangbusters all over again?

Greggs shares have been showing signs of renewed life and Harvey Jones examines whether the battered FTSE 250 bakery chain…

Read more »

Businessman hand stacking money coins with virtual percentage icons
Investing Articles

4,898 shares in British American Tobacco return £12,000 a year in dividends. Worth it?

A falling share price means a higher dividend yield for British American Tobacco shares. Should passive income investors take a…

Read more »

A handsome mature bald bearded black man in a sunglasses and a fashionable blue or teal costume with a tie is standing in front of a wall made of striped wooden timbers and fastening a suit button
Growth Shares

As it swallows up more firms, this penny stock looks primed to head higher

Jon Smith reviews a penny stock that has caught his attention, with its acquisition strategy proving to help increase the…

Read more »

Array of piggy banks in saturated colours on high colour contrast background
Investing Articles

£5,000 invested in HSBC shares in an ISA 5 years ago is now worth…

HSBC has made for a stunning investment. Andrew Mackie assesses whether new ISA investors could still see similar returns over…

Read more »

Two female adult friends walking through the city streets at Christmas. They are talking and smiling as they do some Christmas shopping.
Investing Articles

This UK income stock yields an eye-popping 7.3% but can it afford to keep growing its dividend?

Harvey Jones examines an income stock with a sky-high yield, because he wants to be sure it can keep the…

Read more »

Rolls-Royce's Pearl 10X engine series
Investing Articles

Is the best still to come for Rolls-Royce shares?

Christopher Ruane explains why he thinks Rolls-Royce shares could yet push even higher from here -- and whether he's ready…

Read more »